 Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lower doses of CG-806, and the expansion to 750mg and possibly higher doses could finally drive meaningful responses. 